SCHEMBL1005012

SCHEMBL1005012

c1ccc2c(c1)-c1ccccc1-c1ccccc1-c1ccccc1-c1ccccc1-c1ccccc1-2

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.61
KMT2A Q03164 4/20 0.61
MAPK1 P28482 3/20 0.61
NPC1 O15118 2/20 0.61
MAOA P21397 2/20 0.61
SMN1; SMN2 Q16637 2/20 0.61
S100A4 P26447 2/20 0.61
APAF1 O14727 2/20 0.61
TDP2 O95551 2/20 0.61
KDM4E B2RXH2 1/20 0.61
CES2 O00748 1/20 0.61
TERT O14746 1/20 0.61
PLIN1 O60240 1/20 0.61
S1PR4 O95977 1/20 0.61
LMNA P02545 1/20 0.61
PLA2G1B P04054 1/20 0.61
BCHE P06276 1/20 0.61
POLB P06746 1/20 0.61
PTPRC P08575 1/20 0.61
MAPT P10636 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29543474 1.00 MEN1 (0.61) MEN1KMT2AMAPK1NPC1MAOA
SCHEMBL29437946 1.00 MEN1 (0.61) MEN1KMT2AMAPK1NPC1MAOA
SCHEMBL28694051 1.00 MEN1 (0.61) MEN1KMT2AMAPK1NPC1MAOA
SCHEMBL28904690 1.00 MEN1 (0.61) MEN1KMT2AMAPK1NPC1MAOA
SCHEMBL4368339 1.00 MEN1 (0.61) MEN1KMT2AMAPK1NPC1MAOA
SCHEMBL58152 1.00 MEN1 (0.61) MEN1KMT2AMAPK1NPC1MAOA
SCHEMBL29711875 1.00 MEN1 (0.61) MEN1KMT2AMAPK1NPC1MAOA
SCHEMBL29067593 1.00 MEN1 (0.61) MEN1KMT2AMAPK1NPC1MAOA
SCHEMBL49870 1.00 MEN1 (0.61) MEN1KMT2AMAPK1NPC1MAOA
SCHEMBL11875421 1.00 MEN1 (0.61) MEN1KMT2AMAPK1NPC1MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 361 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119978007-A Condensed cyclic compound and organic light-emitting device comprising the same 三星显示有限公司 2025-05-13 CN claimed
CN-119768014-A Heterocyclic compound, organic light-emitting device, and electronic device 三星显示有限公司 2025-04-04 CN claimed
CN-113717057-B Amine compound and organic light emitting device including the same 三星显示有限公司 2025-04-01 CN claimed
CN-111293234-B Organic light emitting device and electronic apparatus 三星显示有限公司 2025-02-21 CN claimed
CN-111384300-B Organic light emitting device and apparatus including the same 三星电子株式会社 2025-01-17 CN claimed
CN-112838172-B Organic light emitting device 三星显示有限公司 2024-08-09 CN claimed
CN-118201453-A Amine-based compound, light-emitting device, electronic apparatus, and electronic device 三星显示有限公司 2024-06-14 CN claimed
CN-109400486-B Amine compound and organic light emitting device including the same 三星显示有限公司 2023-10-13 CN claimed
CN-109560214-B organic light emitting device 三星显示有限公司 2023-08-29 CN claimed
CN-111740024-B organic light emitting device 三星显示有限公司 2023-08-25 CN claimed
US-20040029861-A1 Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression KLINGE PHARMA GMBH 2004-02-12 US claimed
US-20040009967-A1 Pyridyl alkene- and pyridyl alkine- acid amides as cytostatics and immuno-suppressives KLINGE PHARMA GMBH 2004-01-15 US claimed
US-20030162972-A1 Pyridyl alkane acid amides as cytostatics and immunosupressives KLINGE PHARMA GMBH 2003-08-28 US claimed
JP-2000512652-A 2000-09-26 JP claimed
EP-0934309-A1 NEW PYRIDYL ALKANE ACID AMIDES AS CYTOSTATICS AND IMMUNOSUPPRESSIVES Klinge Pharma GmbH (DE) 1999-08-11 EP claimed
EP-0923570-A1 PYRIDYL ALKENE- AND PYRIDYL ALKINE- ACID AMIDES AS CYTOSTATICS AND IMMUNOSUPPRESSIVES Klinge Pharma GmbH (DE) 1999-06-23 EP claimed
EP-0912176-A1 USE OF PYRIDYL ALKANE, PYRIDYL ALKENE AND/OR PYRIDYL ALKINE ACID AMIDES IN THE TREATMENT OF TUMORS OR FOR IMMUNOSUPPRESSION Klinge Pharma GmbH (DE) 1999-05-06 EP claimed
WO-1997048696-A1 PYRIDYL ALKENE- AND PYRIDYL ALKINE- ACID AMIDES AS CYTOSTATICS AND IMMUNOSUPPRESSIVES KLINGE PHARMA GMBH (DE) 1997-12-24 WO claimed
WO-1997048397-A1 USE OF PYRIDYL ALKANE, PYRIDYL ALKENE AND/OR PYRIDYL ALKINE ACID AMIDES IN THE TREATMENT OF TUMORS OR FOR IMMUNOSUPPRESSION KLINGE PHARMA GMBH (DE) 1997-12-24 WO claimed
WO-1997048695-A1 NEW PYRIDYL ALKANE ACID AMIDES AS CYTOSTATICS AND IMMUNOSUPPRESSIVES KLINGE PHARMA GMBH (DE) 1997-12-24 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009967-A1 Pyridyl alkene- and pyridyl alkine- acid amides as cytostatics and immuno-suppressives IDO1, ALK, ARG1 MEN1 2138/4885KMT2A 1694/4885MAPK1 1160/4885
US-20040029861-A1 Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression ALK, IDO1, PDXK MEN1 866/4885KMT2A 1493/4885MAPK1 549/4885
US-20030162972-A1 Pyridyl alkane acid amides as cytostatics and immunosupressives ALK, TYMP, ANXA1 MEN1 1667/4885KMT2A 1559/4885MAPK1 462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.